Ista Pharmaceuticals Inc

Ista Pharmaceuticals — Investor Presentation (December 2011)

24 slides from Ista Pharmaceuticals's investor presentation, Dec 22, 2011

  1. Slide 1: Investor Presentation December 2011

    Exhibit 99.1 Investor Presentation December 2011

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Certain statements contained herein are “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied

  3. Slide 3: Company Timeline

    Company Timeline BROMDAY™ XIBROM™ BEPREVE® ISTALOL® VITRASE® 1992 2000 2002 2004 2005 2009 2010 Acquired ISTALOL & XIBROM Revenue ISTA >$100 million Profitable* Name change to ISTA Pharmaceuticals, Inc. IPO on NASDAQ Founded as Advanced Corneal Systems * On an adjusted cash net income basis ISTA PHA

  4. Slide 4: ISTA's Track Record of Success

    ISTA’s Track Record of Success • Thriving core Rx eye business, emerging Rx allergy franchise – Third largest branded Rx eye care company in U.S. • Obtained 5 Rx eye and allergy product approvals in 6 years – ISTALOL, VITRASE, XIBROM, BEPREVE, BROMDAY – Products are #1 or #2 in their markets with ma

  5. Slide 5: 2011 – Solid Commercial and Pipeline Progress

    2011 – Solid Commercial and Pipeline Progress • Highly successful switch from XIBROM to BROMDAY • BEPREVE projected to increase significantly over 2010 • Strong pipeline progress, de-risking of programs – PROLENSA™ Phase 3 successful – BEPOMAX™ Phase 2 successful, BEPOSONE™ to enter Phase 2 shortly

  6. Slide 6: Current Commercial Products

    Current Commercial Products $300 Million Mid-Term Potential Revenue BROMDAY™ BEPREVE® Only once-daily Fast growing, twice-daily prescription eye drop for prescription eye drop for postoperative ocular itching associated inflammation and with allergic conjunctivitis reduction of ocular pain in patien

  7. Slide 7: BROMDAY

    BROMDAY TM Convenient Once-Daily Dosing The ONLY approved once-daily Rx non-steroidal anti-inflammatory (NSAID) eye drop for pain and inflammation post-cataract surgery • BROMDAY October 2011 prescriptions EstimatedNSAID2011MarketSizeTRx$: ~$367MM equal to highest level achieved by Based on Nov 2011

  8. Slide 8: BROMDAY Outlook Strong

    BROMDAY Outlook Strong Prescription Dollars Reflect Increasing Average Price 35.0% BROMDAY Market Shares 33% 30.0% #1 in Total Prescription Dollars (TRx$) 25.0% 24% Achieved 33% TRx$ share in 20.0% only 13 months 15.0% 10.0% 5.0% 0.0% Oct-10 Nov-10 Dec-10 Jan-11 Feb-11 Mar-11 Apr-11 May-11 Jun-11 Ju

  9. Slide 9: BEPREVE

    BEPREVE ® Near-term tactical drivers in place Opportunity for BEPREVE to gain additional market share • Twice-daily antihistamine eye drop to treat 2011EstimatedAllergyMarket: ~$780MM itching associated with allergic conjunctivitis Nov 2011 Rolling 12 Month TRx • Projected 2011 revenues to grow sign

  10. Slide 10: ISTALOL and VITRASE

    ISTALOL and VITRASE Established base products • ISTALOL – Market-leading once daily beta-blocker eye drop for glaucoma – Growth through share gain and pricing – 2010 market size: ~$ 180 million – Patent protection to 2018 • VITRASE – Injectable biologic spreading agent, hyaluronidase, used to enhanc

  11. Slide 11: ISTA's Robust Near-Term Pipeline

    ISTA’s Robust Near-Term Pipeline Launches Drive Revenues to $500 by 2015* Formulation Phase 1 Phase 2 Phase 3 2015 Est. Candidates** Market Size OTC eye products Dry eye $300 million PROLENSA Ocular Inflammation & Pain $500+ million Low-concentration bromfenac T-PRED Ocular Inflammation / Infection

  12. Slide 12: OTC Eye Products

    OTC Eye Products Expansion of Rx Business into High- Operating Margin Consumer Cash Business Existing sales force to drive practitioner-recommended sales • Over-the-Counter eye drops for treatment of dry eye and other ocular conditions • OTC developed and tested in 2011 during prescription dry eye P

  13. Slide 13: PROLENSA

    PROLENSA ™ New Formula with Pending Patents through 2024 Key extension of successful bromfenac business • Bromfenac-based NSAID for ocular pain and inflammation associatedwith cataractextraction– projectedto replaceBROMDAY • PositivePhase3 StudyResultsReportedOct.2011– Clinicalwork done – Lowest num

  14. Slide 14: T-Pred

    T-Pred Promising Anti-Infective/Steroid Ideal supplemental product to leverage sales infrastructure • Fixed combination prednisolone & tobramycin prescription eye drop • For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocul

  15. Slide 15: BEPOMAX

    BEPOMAX Major Extension of Allergy Franchise Large Market Opportunity Exists 2015 Potential: ~$400+ million • Single agent antihistamine nasal spray • Active ingredient, bepotastine, already approved in Rx eye drop BEPREVE • For treatment of seasonal allergic rhinitis • Positive Phase 2 Study result

  16. Slide 16: BEPOSONE

    BEPOSONE ™ "Holy-Grail" Rx Nasal Allergy Product Large Market Opportunity Exists 2015 Potential: $2+ Billion • Combination patented antihistamine / steroid • Antihistamine, bepotastine, already approved in Rx eye drop BEPREVE • For treatment of seasonal allergic rhinitis • Filed Investigational New

  17. Slide 17: Bromfenac Adjunct for AMD

    Bromfenac Adjunct for AMD Lower-Risk "Back of the Eye" Approach Continued growth of successful bromfenac franchise • Higher-concentration, new formulation of bromfenac • For adjunctive treatment of age-related macular degeneration (AMD) • Paper published in Sept 2011 Issue of RETINA suggests bromfen

  18. Slide 18: ISTA's Key Patents and Applications

    ISTA’s Key Patents and Applications PRODUCT(S) PATENT(S) AND EXPIRATION KEY CLAIM(S) BEPREVE ISSUED Bepotastine API and methods of mfg. (composition of matter for Exp: Dec 2017 , filed for extension to Sept 2019 Bepotastine besilate) BEPOSONE APPLICATION Aqueous formulation Estimated Exp: July 2023

  19. Slide 19: ISTA Strategy for Long-Term Success

    ISTA Strategy for Long-Term Success Marketed Product Business Products Pipeline Development • PROLENSA (low- • Acquire marketed products concentration bromfenac) • License late stage assets • T-PRED in 2013+ BROMDAY ISTALOL VITRASE • BEPOMAX nasal spray • Acquire marketed products • BEPOSONE combo •

  20. Slide 20: Business Development

    Business Development External Value Creation • Disciplined approach to evaluation of opportunities • Rx Eye and Rx Allergy for growth and commercial synergy – Acquire marketed or soon-to-be marketed products – License late-stage products – Partner for access to primary care physicians and consumer b

  21. Slide 21: ISTA: Fast-Growing, Niche Pharmaceutical Company

    ISTA Fast-Growing, Niche Pharmaceutical Company Outlook$160 –$175 ISTA PHARMACEUTICALS 21

  22. Slide 22: 2012 Guidance and Pipeline Update

    2012 Guidance and Pipeline Update • WebcastandConferencecall – Jan.4, 2012 4:30 pm ET – Internet: http://www.istavision.com/investors.html – Domestic dial-in: 866-270-6057 International : 617-213-8891 – Passcode: 58694464 ISTA PHARMACEUTICALS 22

  23. Slide 23: Realizing Value - Looking to 2015 and Beyond

    Realizing Value - Looking to 2015 and Beyond • "5 in 5" – 5 new product launches in next 5 years • Rx Eye, Rx Allergy, Over-the-Counter – $500 million in revenues by 2015 • Forecasted compounded 5-year revenue growth rate ~ 40% • Organic growth from current products drives revenues majority growth o

  24. Slide 24: A Pharmaceuticals’

    A Pharmaceuticals’

Ista Pharmaceuticals — Investor Presentation (December 2011) on 6ix